tbuckley/cabot-search huggingface dataset:
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma
Authors: Amy Barone, Maitreyee Hazarika, Marc R. Theoret, Pallavi Mishra-Kalyani, Huanyu Chen, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Elimika Pfuma, Yaning Wang, Hongshan Li, Hong Zhao, Jeanne Fourie Zirkelbach, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2017)

On December 18, 2015, the FDA granted regular approval to pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) for treatment of patients with unresectable or metastatic melanoma based on results of two randomized, open-label, active-controlled clinical trials. In trial PN006, 834 patients with ipilimumab-naïve metastatic melanoma were randomized (1:1:1) to pembrolizumab 10 mg/kg i.v. every 2 or 3 weeks until disease progression or ipilimumab 3 mg/kg every 3 weeks for up to four doses. In trial PN002, 540 patients with ipilimumab-refractory metastatic melanoma were randomized (1:1:1) to pembrolizumab 2 or 10 mg/kg i.v. every 3 weeks or to investigator's choice of chemotherapy. In trial PN006, patients randomized to pembrolizumab demonstrated a statistically significant improvement in overall survival compared with ipilimumab [every-2-week arm: hazard ratio (HR) = 0.63; 95% confidence interval (CI), 0.47-0.83; P < 0.001; every-3-week arm: HR = 0.69; 95% CI, 0.52-0.90; P = 0.004]. In both trials, patients receiving pembrolizumab demonstrated statistically significant improvements in progression-free survival. The most common (≥2%) immune-mediated adverse reactions in a pooled safety analysis were hypothyroidism, pneumonitis, and hyperthyroidism. Key considerations for approval were determination of pembrolizumab dose and interpretation of tumor response-based endpoints using RECIST or immune-related RECIST. Clin Cancer Res; 23(19); 5661-5. ©2017 AACR.
A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C)
Authors: C. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schultz, D. Richards, B. Wang, M. Morrison
Journal: Journal of Clinical Oncology (2006)

3506 Background: This multicenter, randomized study assessed efficacy &amp; safety for 3 irinotecan/fluoropyrimidines combinations in previously untreated mCRC. In a 3 × 2 factorial design, we also assessed whether celecoxib added to chemotherapy (CT) improved CT efficacy and/or reduced toxicity. Methods: Pts were randomized to: FOLFIRI - irinotecan (I) 180 mg/m 2 , leucovorin (LV) 400 mg/m 2 , 5-FU bolus 400 mg/m 2 , &amp; infusional 5-FU 2400 mg/m 2 over 46 hours q 2 wks; modified IFL (m-IFL) - I 125 mg/m 2 , LV 20 mg/m 2 , &amp; bolus 5-FU 500 mg/m 2 wkly × 2, q 3 wks; or CapeIri - I 250 mg/m 2 day 1 &amp; capecitabine 1000 mg/m 2 po BID × 14 days, q 3 wks. Pts were also randomized to concurrent celecoxib (400 mg po BID) or placebo in a double-blind fashion. Time to progression (TTP) was the primary endpoint. Results: 430 pts were enrolled from 2/03 to 4/04, prior to an amendment that added bevacizumab to CT arms. Baseline characteristics were balanced. TTP for FOLFIRI (median = 8.2 mos) was significantly better than for either m-IFL (6.0 mos; p = 0.01) or CapeIri (5.7 mos; p = 0.01). Overall survival (OS) also favored FOLFIRI (median = 23.1 mos) compared to either m-IFL (17.6 mos; p=0.10) or CapeIri (18.8 mos; p = 0.19). Common grade ≥ 3 toxicities are listed below. CapeIri had the highest rates of nausea, vomiting, diarrhea, dehydration &amp; hand-foot syndrome, whereas FOLFIRI had lower rates. Among all 430 pts, median TTP did not differ for pts randomized to celecoxib compared to placebo (6.9 vs 6.9 mos; p=0.71). Median OS was also similar for celecoxib vs placebo (19.5 vs 18.8 mos; p=0.63). CT toxicities did not differ for celecoxib vs placebo. Rates for MI/stroke were 1.5% for celecoxib and 1.9% for placebo. Conclusions: First-line FOLFIRI offers a superior TTP when compared to m-IFL or CapeIri; OS &amp; toxicity analyses also favored FOLFIRI. Celecoxib neither improved CT efficacy nor reduced CT toxicity. Updated survival data &amp; data on pts enrolled after the addition of bevacuzimab will be presented. [Table: see text] [Table: see text]
Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database
Authors: A. Bamias, K. Tzannis, M. Liontos, L. Harshman, S.J. Crabb, Y.-N. Wong, S.K. Pal, T.B. Powles, J. Bellmunt, U. De Giorgi, S. Ladoire, N. Agarwal, E.Y. Yu, G. Niegisch, C.N. Sternberg, A. Alva, S. Srinivas, J. Rosenberg, R. Investigators
Journal: Annals of Oncology (2016)
Having a Conversation With a Patient With Incurable Cancer—Just Another Protocol?
Authors: Jacqueline Stouthard, Linda Brom, Hilde M. Buiting
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
324P Radiation response assessment by hybrid positron emission tomography/magnetic resonance imaging for cervical cancer treatment
Authors: B.A. Choo, V. Koh, J. Tang, J. Low, M.C. Stephenson, D.L.-H. Cheong, E. Laurens, J.J. Totman, J.S.-Y. Ng, S. Roy
Journal: Annals of Oncology (2016)
A New Non-Dilution Protocol of Rapid Desensitization for Platinum Hypersensitivity
Authors: Hye-Ryun Kang, Jisu Shim, Soo Jie Chung, Sung-Yoon Kang, Kyoung-hee Sohn, Woo-Jung Song, Heung-Woo Park, Sang-Heon Cho
Journal: Journal of Allergy and Clinical Immunology (2017)
441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Authors: B.B.Y. Ma, C.M. Rudin, A. Cervantes, A. Dowlati, D. Costa, P. Schmid, R. Heist, V.M. Villaflor, I. Sarkar, M.A. Huseni, P. Foster, C. O’Hear, S. Gettinger, B. Besse
Journal: Annals of Oncology (2016)
Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities
Authors: Sjoerd A.M.E.G. Timmermans, Myrurgia A. Abdul-Hamid, Joris Vanderlocht, Jan G.M.C. Damoiseaux, Chris P. Reutelingsperger, Pieter van Paassen, F. de Heer, M. Krekels, F. Stifft, G. Verseput, S. Boorsma, W. Grave, J. Huitema, J. Wirtz, N. ter Braak, L. Frenken, S. Gaertner, M. Christiaans, T. Fung, M. Gelens, J. Kooman, K. Leunissen, E. Litjens, J. van der Net, F. van der Sande, E. van Duijnhoven
Journal: Kidney International (2017)
Abstract 11770: Egg Consumption and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis
Authors: Chayakrit Krittanawong, Anusith Tunhasiriwet, Marysia S Tweet, Kimberly J Bisanz, Sakkarin Chirapongsathorn, Matthew B Hoy, Zhen Wang, Sharonne N Hayes
Journal: Circulation (2015)

Introduction: Current dietary guidelines no longer recommend against egg consumption despite the high cholesterol content. However, considerable controversy remains on the relationship between high egg consumption and cardiovascular disease (CVD) risk. The objective of this systematic review and meta-analysis was to explore the association between egg consumption and CVD events. Methods: We systematically searched PubMed, Scopus, and the Cochrane Database of Systematic Reviews from database inception through April 2015 for observational studies with hazard ratio (HRs) or relative risks (RRs) and 95% confidence intervals (95% CI) that reported the association between egg consumption and CVD events which included coronary heart disease (CHD) and stroke. Data were extracted by one reviewer followed by independent screening and extraction of study characteristics and outcome data by two other reviewers. Conflicts were resolved through consensus. Random-effects meta-analyses were used to pool the hazard ratios or relative risks from the included studies. Subgroup analyses were performed to explore the potential sources of heterogeneity. The quality of the included studies and publication bias were assessed. Results: We identified 5 cross-sectional and 6 prospective studies with median follow-up of 13.1 years. A total of 301,339 individuals and 10,262 total CVD events were included with 7,225 CHD and 3,037 stroke cases. Compared to consumption of less than 1 egg/day, higher egg consumption was associated with an increased risk of CVD events (pooled HR, 1.43; 95% CI, 1.01-2.03; p=0.012; I 2 = 65.7% and pooled RR, 1.09; 95% CI, 0.89-1.34; p=0.145; I 2 = 41.4%). Conclusions: Our analysis suggests that higher consumption of eggs (more than 1 egg/day) may be associated with increased risk of cardiovascular disease. Large and diverse prospective community-based cohorts will be necessary to establish optimal dietary recommendations for public health.
Allogeneic Transplant with Standard Conditioning, Reduced Intensity, or Non-Myeloablative Conditioning Regimen for Multiple Myeloma (MM).
Authors: Firoozeh Sahebi, Neil M. Kogut, Ricardo Spielberger, Peter M. Falk, Auayporn P. Nademanee, Leslie Popplewell, David G. Maloney, Roberto Rodriguez, Amrita Krishnan, Ryotaro Nakamura, Margaret R. O’Donnell, Parker M. Pablo, Eileen P. Smith, Anthony S. Stein, David S. Snyder, Jasmine M. Zain, Dajun Qian, Stephen J. Forman, George Somlo
Journal: Blood (2005)
Inhibition of Prothrombinase and Not Soluble Factor Xa (fXa) Predicts Efficacy of fXa Inhibitors in an In Vivo Model of Deep Vein Thrombosis.
Authors: Suzanne Delaney, Ann Arfsten, Sherin Halfon, Gail Siu, John Malinowski, Penglie Zhang, Shaun Bauer, Zhaozhong Jia, Bingyan Zhu, Gary Park, Stanley Hollenbach, Uma Sinha
Journal: Blood (2006)
Retinoblastoma Related Gene RB2/P130 Are Rarely Mutated in Burkitt’s Lymphoma from Brazil.
Authors: Claudete E. Klumb, Eliane P.S. Magluta, Roberta S. Facion, Lidia Maria M. Rezende, Alexandre G. Apa, Maria K. Carrico, Joao F. Alonso, Raquel C. Maia
Journal: Blood (2005)
RTHP-27. PHASE I/II STUDY OF DDFPe AS A RADIOSENSITIZER IN GLIOBLASTOMA
Authors: Evan Unger, Ralph Mason, Heling Zhou, Michael Sellenger, Jeremy Ruben, Jason Lickliter, Olivia Longacre
Journal: Neuro-Oncology (2016)

Describe the interim results of a Phase Ib/II clinical trial of dodecafluoropentane emulsion (DDFPe) as a radiosensitizer in chemoradiation of glioblastoma multiforme (GBM). With informed consent and IRB approval 10 adult GBM patients have been enrolled in the trial. Patients are administered IV DDFPe (2% w/vol at doses of 0.05 mL/kg, 0.1 mL/ kg or 0.17 mL/kg) 30-60 minutes prior to radiation therapy with oxygen or carbogen breathing. To confirm tumor re-oxygenation, patients underwent TOLD MRI before and after DDFPe administration. Patients were treated with 30 fractions of radiotherapy (2 Gy each). Archived tumor specimens are studied with GliomaSTRAT® assay for methylated genes predictive of response. Patients were also studied with serial MR scans as per standard of care and for survival. One patient received the 0.05 mL/kg dose, 8 patients received the 0.1 mL/kg dose and 1 patient received the 0.17 mL/kg dose. There were no acute adverse events related to administration of DDFPe. One patient at each of dose levels 0.1 mL/kg and 0.17 mL/kg developed symptomatic radiation necrosis (confirmed by histopathology), which was judged to be related to DDFPe. Enrollment has continued at the 0.1 mL/kg dose without additional significant DDFPe-related toxicity. TOLD MRI showed significant decrease in T1 of tumor tissue consistent with tumor re-oxygenation. First patient was predicted temozolomide (TMZ) non-responder (TMZ-) and survived 21 months. Second patient (TMZ+) is alive 20 months. Third patient (TMZ-) who had excessive radiation necrosis is alive at 15 months and improving symptomatically. All other patients are alive but less than 1-year follow-up at this time. DDFPe is a promising oxygen therapeutic for reversing tumor hypoxia and merits Phase II study.
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Authors: Lorenzo Guglielmetti, Marie Jaspard, Damien Le Dû, Marie Lachâtre, Dhiba Marigot-Outtandy, Christine Bernard, Nicolas Veziris, Jérôme Robert, Yazdan Yazdanpanah, Eric Caumes, Mathilde Fréchet-Jachym
Journal: European Respiratory Journal (2016)

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients treated with this drug outside clinical trials. All MDR-TB patients who started treatment from January 1, 2011 to December 31, 2013 and received ≥30 days of bedaquiline were included in a multicentre observational cohort. Among 45 MDR-TB patients, 53% harboured isolates resistant to both fluoroquinolones and second-line injectables, and 38% harboured isolates resistant to one of these drug classes. Median bedaquiline treatment duration was 361 days and 33 patients (73%) received prolonged (&gt;190 days) bedaquiline treatment. Overall, 36 patients (80%) had favourable outcome, five were lost to follow-up, three died, and one failed and acquired bedaquiline resistance. No cases of recurrence were reported. Severe and serious adverse events were recorded in 60% and 18% of patients, respectively. Values of Fridericia-corrected QT interval (QTcF) &gt;500 ms were recorded in 11% of patients, but neither arrhythmias nor symptomatic cardiac side-effects occurred. Bedaquiline was discontinued in three patients following QTcF prolongation. No significant differences in outcomes or adverse events rates were observed between patients receiving standard and prolonged bedaquiline treatment. Bedaquiline-containing regimens achieved favourable outcomes in a large proportion of patients. Prolonged bedaquiline treatment was overall well tolerated in this cohort.
Complete remission of bone metastases in androgen receptor - positive (ar+) salivary duct carcinoma (sdc) of the parotid treated with radium 223
Authors: M. Airoldi, F. Pedani, E. Bellini, V. Contu, M. Tucci, T. Angusti, M. Garzaro, L. Raimondo, G. Pecorari
Journal: Annals of Oncology (2016)
Induction of Cyclin D1 Gene in Myeloma Cells Down-Regulates the Expression of Cyclin D2.
Authors: Yoshiaki Kuroda, Akira Sakai, Naohiro Tsuyama, Mami Mizuno, Nanae Nakaju, Shoso Munemasa, Yoshiko Okikawa, Yuta Katayama, Akiro Kimura
Journal: Blood (2005)
The Notch Ligand DLL4 Derived from Human Dendritic Cells Is Critical for Promoting T Helper (Th)1 and Th17 Cell Differentiation
Authors: Lijun Meng, Zhenjiang Bai, Shan He, Kazuhiro Mochizuki, Janaki Purushe, Hongxing Sun, Jian Wang, Hideo Yagita, Shin Mineishi, Henry Fung, Gregory A. Yanik, Roberto Caricchio, Xiaoxuan Fan, Lisa M Crisalli, Ran Reshef, Yanyun Zhang, Yi Zhang
Journal: Blood (2015)
Fertility Preservation for Women with Sickle Cell Disease (SCD)
Authors: Torie C Plowden, Nicole M Millan, Carter M Owen, Mae W Healy, Nicole K Banks, Matthew Hsieh, Courtney D. Fitzhugh, Jeannine Witmyer, Doug Peak, David Frankfurter, Alan H DeCherney, John F Tisdale, Erin F Wolff
Journal: Blood (2015)
Immunotherapy-associated autoimmune hemolytic anemia
Authors: Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka, Tarik Hadid
Journal: Journal for ImmunoTherapy of Cancer (2017)

Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) pathway are the prototypic checkpoint targets for immunotherapy. When combined, CTLA-4 and PD-1 checkpoint inhibitors work synergistically, but with increased probability of toxicity. The following case represents an unusual adverse effect of combined treatment with ipilimumab and nivolumab used for treatment of metastatic melanoma.A 43-year-old woman with metastatic melanoma presented with severe generalized weakness and fatigue. She has received two cycles of ipilimumab and nivolumab, last administered 3 weeks prior to her presentation. Initial investigations revealed severe anemia with appropriate reticulocytosis, severely elevated lactate dehydrogenase, undetectable haptoglobin level and positive direct coombs test. Patient was diagnosed with severe autoimmune hemolytic anemia secondary to ipilimumab and nivolumab. She was successfully treated with high dose steroids and rituximab.In our case, we present a rare but serious adverse effect of immunotherapy. We illustrate the clinical presentation and management of immunotherapy associated autoimmune hemolytic anemia. Immunotherapy has revolutionized the treatment of many malignant conditions; therefore, it is imperative for health care professionals caring for cancer patient to be familiar with the adverse effects of immunotherapy, which allow for early recognition and management of these potentially lethal side effects.
Expression and activity of PXR target genes CYP3A4 and MDR1 in sarcoma tumors predict response to chemotherapeutic agents
Authors: Edith J. Mensah-Osman, Dafydd Thomas, Thomas Giordano, Michelle Lizyness, Paul Hollenberg, Laurence Baker
Journal: Cancer Research (2004)

4754  Objectives: We tested the hypothesis that orphan steroid pregnane X receptor (PXR) modulation of target genes involved in drug metabolism and transport may be involved in drug resistance of sarcomas. We examined cytotoxicity, inducibility, expression and activity of CYP3A4/5 and the multidrug resistance gene (MDR1) using a specific PXR ligand, rifampin, and selected chemotherapeutic agents in primary sarcoma cell lines. Methods: Total RNA from primary sarcoma cell lines was extracted before and after exposure to etoposide, doxorubicin, ifosfamide, rifampin or phenobarbitol and real-time PCR assays carried out for CYP3A4/5, PXR and MDR1. Protein expression was measured by western blot analysis. Catalytic activity of CYP3A was measured using 7-benzyl-trifluoromethyl coumarin, a CYP3A specific substrate, and/or testosterone 6β-hydroxylation, and a rhodamine 123 assay was used to measure MDR1 activity. Cytotoxicity was determined by lactate dehydrogenase release, Bax/Bcl-2 ratios and PARP cleavage and/or annexin V staining. Results: We observed variations in baseline gene and protein expression of CYP3A4/5, PXR and MDR1 in the different primary sarcoma cell lines. Furthermore, differences were observed in the induction, expression and activity of CYP3A4/5 and MDR1 in response to the PXR specific ligand, rifampin, and the xenobiotics mentioned above, which correlate with the cytotoxic effects of the chemotherapeutic agents. Our results suggest substantial differences in the cytotoxicity profile mediated by these genes. Resistance of primary sarcoma cell lines to etoposide correlated best with increased CYP3A activity and PXR protein expression. Interestingly, while rifampin showed a selective increase in CYP3A activity without any cytotoxic effect, etoposide induced CYP3A activity with variable cytotoxicity in sarcoma cell lines much more efficiently than rifampin, and the activity was reversible by ketoconazole, a CYP3A4 inhibitor. MDR1 expression and function in tumor cells correlated with resistance to doxorubicin, while ifosfamide sensitivity correlated best with baseline CYP3A activity in the tumor. Conclusion: We speculate that one mechanism of etoposide resistance in sarcoma occurs due to binding on PXR and conclude that expression and functional activity of PXR and target genes CYP3A4 and MDR1 in sarcoma tumors may play an important role in resistance and may be used as biomarkers of therapeutic response.
PU.1 Is Downregulated in a Subset of Multiple Myeloma by the Methylation of Its -17 kb Upstream Regulatory Region and the Promoter.
Authors: Yutaka Okuno, Hiro Tatetsu, Shikiko Ueno, Hiroyuki Hata, Yasuhiro Yamada, Motohiro Takeya, Tadafumi Iino, Koichi Akashi, Daniel G. Tenen, Hiroaki Mitsuya
Journal: Blood (2006)
R-da-EPOCH vs R-CHOP in patients with primary mediastinal large B-cell lymphoma: Results of randomised (prospective) multicenter study
Authors: I. Kryachok, I. Stepanishyna, I. Tytorenko, A.V. Martynchyk, K. Filonenko, O. Novosad, T. Kadnikova, I. Pastushenko, Y. Kushchevyy, T. Skrypets, O. Aleksyk, K. Ulianchenko
Journal: Annals of Oncology (2016)
STAT3 Signaling in Donor-Derived CD4+ T-Cells Plays a Critical Role in the Induction of Acute and Chronic GVHD in Murine Models of alloBMT.
Authors: Vedran Radojcic, Maria A. Pletneva, Hung-Rong Yen, Timothy J. Harris, Drew M. Pardoll, Charles G. Drake, Leo Luznik
Journal: Blood (2007)
STMC-35. DIVERGENT Wnt SIGNALING REGULATES GLIOMA STEM CELLS AND TUMOR PHENOTYPE
Authors: Angel Alvarez, Tianzhi Huang, Rajendra Pangeni, Songijan Lu, Cameron Brennan, Erik Sulman, Xinghua Lu, Ichiro Nakano, Wei Zhang, Zhou Zhang, Bo Hu, Shi-Yuan Cheng
Journal: Neuro-Oncology (2016)

Glioblastomas (GBMs), the most aggressive adult brain tumor, can be classified into clinically relevant subtypes based on gene expression and genomic alterations that influence survival and treatment response. Additionally, glioma stem cells (GSCs) are recognized as unique subpopulations that contribute to tumorigenesis, recurrence, and therapy resistance. Because Wnt signaling is critical in neural stem cell growth, we hypothesized the Wnt pathway would regulate GSCs and glioma subtypes. We have characterized two distinct subtypes of GSCs, proneural (PN) and mesenchymal (MES), by gene expression profiling, in vitro growth, and radiation response. Subsequent analysis of differentially expressed transcripts between GSCs and patient glioma subtypes identified activators of the canonical Wnt pathway enriched in the proneural subtype, while inhibitors are up-regulated in the mesenchymal. Wnt signaling genes predicted radiation resistance and were prognostic factors for patient survival, with high canonical Wnt signaling predictive of prolonged survival. We validated these results in multiple independent data sets, including TCGA glioma patient data. To further investigate the relationship between Wnt signaling, tumor subtype, and malignancy, we measured protein expression and genome-wide methylation using a panel of subtyped GSCs. Proneural GSCs expressed higher levels of s9-phosphorylated GSK3β and transcription factor Sox2, while mesenchymal GSCs had greater expression of CD44 and FZD6, an inhibitor of canonical Wnt signaling. Methylation analysis shows Wnt signaling is also regulated at the epigenetic level, given the subtype-dependent methylation pattern of pathway genes. Finally, we identify a significant inverse relationship between canonical Wnt signaling and the T-cell signature, suggesting the role of the Wnt pathway in regulating immune response and the tumor microenvironment. Our results reveal the clinical significance of Wnt signaling in predicting glioma subtype, radiation response, and patient survival. These exciting results reveal potential therapeutic options in treating aggressive tumors and targeting cancer stem cells in a more personalized-medicine approach.